Date: 2012-05-21
Type of information: Grant
Company: ElexoPharm (Germany)
Investors: German Federal Ministry of Education and Research (BMBF) (Germany)
European Commission
Amount: € 2.1 Million
Funding type: grant
Planned used: During the three years’ grant period, each partner of this multidisciplinary European consortium will contribute its expertise to reach their shared goal. ElexoPharm is responsible for the design and synthesis of small pharmaceutical molecules with state of the art in silico modelling and medicinal chemistry technologies. Khondrion acts as the consortium leader and will carry out the in vitro evaluation of the new chemical entities, including screening in their cell-based mitochondrial disease models. Pharmacelsus is going to perform ADME, toxicity and PK studies in their GLP-certified facilities, and the RUNMC will evaluate the best compounds regarding in vivo efficacy in preclinical studies to achieve Proof of Principle.
Others: ElexoPharm has received € 2.1 Million EUROSTARS Grant for program targeting mitochondrial diseases. this grant has been awarded to a transnational consortium consisting of Khondrion BV ( Nijmegen ), Radboud University Nijmegen Medical Centre (RUNMC, Nijmegen ), Pharmacelsus GmbH (Saarbruecken) and ElexoPharm GmbH (Saarbruecken). This grant, which for the German partners comes from the German Federal Ministry of Education and Research (BMBF), will support an ambitious scientific collaboration to discover treatments for mitochondrial diseases with high unmet medical need (approximately 300,000 patients in industrialized countries).
Therapeutic area: Mitochondrial diseases
